KMDA
HealthcareKamada Ltd.
$7.24
+$0.21 (+2.99%)
Jan 5, 2026
Price History (1Y)
Analysis
Kamada Ltd. is a healthcare company operating in the drug manufacturers - specialty & generic industry within the broader healthcare sector. The company has a market capitalization of $418.19 million and generates revenue of $174.79 million on a trailing twelve-month (TTM) basis, with 420 employees. The company's financial health indicates moderate profitability, with gross margins of 43.8%, operating margins of 16.6%, and profit margins of 11.7%. Kamada Ltd. also demonstrates respectable returns, boasting return on equity (ROE) of 7.9% and return on assets (ROA) of 4.8%. The company's balance sheet is relatively strong, with a debt-to-equity ratio of 4.33 and cash reserves of $72.00 million. Kamada Ltd.'s valuation metrics suggest a P/E ratio of 20.69 on a TTM basis and forward P/E of 15.74. The company has experienced revenue growth of 12.6% year-over-year (YoY) and earnings growth of 28.6% YoY, indicating some momentum in its financial performance. However, there is no dividend yield to report due to the lack of disclosed payout ratio information.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Kamada Ltd.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Visit website →Key Statistics
- Market Cap
- $418.19M
- P/E Ratio
- 20.69
- 52-Week High
- $9.15
- 52-Week Low
- $5.54
- Avg Volume
- 80.37K
- Beta
- 0.21
Company Info
- Exchange
- NMS
- Country
- Israel
- Employees
- 420